These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21062243)

  • 1. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept.
    Valent P
    Curr Cancer Drug Targets; 2011 Jan; 11(1):56-71. PubMed ID: 21062243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
    Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
    Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.
    Valent P; Deininger M
    Leuk Lymphoma; 2008 Apr; 49(4):604-9. PubMed ID: 18398718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia stem cells: the root of chronic myeloid leukemia.
    Zhou H; Xu R
    Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML.
    Valent P; Sadovnik I; Eisenwort G; Bauer K; Herrmann H; Gleixner KV; Schulenburg A; Rabitsch W; Sperr WR; Wolf D
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31470642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
    Shah M; Bhatia R
    Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective elimination of leukemia stem cells: hitting a moving target.
    Crews LA; Jamieson CH
    Cancer Lett; 2013 Sep; 338(1):15-22. PubMed ID: 22906415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amide-linked local anesthetics preferentially target leukemia stem cell through inhibition of Wnt/β-catenin.
    Ni J; Xie T; Xiao M; Xiang W; Wang L
    Biochem Biophys Res Commun; 2018 Sep; 503(2):956-962. PubMed ID: 29932919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34
    Dolinska M; Piccini A; Wong WM; Gelali E; Johansson AS; Klang J; Xiao P; Yektaei-Karin E; Strömberg UO; Mustjoki S; Stenke L; Ekblom M; Qian H
    Biochem Biophys Res Commun; 2017 Aug; 490(2):378-384. PubMed ID: 28623130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.
    Valent P; Bauer K; Sadovnik I; Smiljkovic D; Ivanov D; Herrmann H; Filik Y; Eisenwort G; Sperr WR; Rabitsch W
    Stem Cells Transl Med; 2020 Nov; 9(11):1331-1343. PubMed ID: 32657052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells.
    Li L; Bhatia R
    Curr Opin Hematol; 2015 Jul; 22(4):324-9. PubMed ID: 26049753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.
    Ho TC; LaMere M; Stevens BM; Ashton JM; Myers JR; O'Dwyer KM; Liesveld JL; Mendler JH; Guzman M; Morrissette JD; Zhao J; Wang ES; Wetzler M; Jordan CT; Becker MW
    Blood; 2016 Sep; 128(13):1671-8. PubMed ID: 27421961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia stem cells.
    Kavalerchik E; Goff D; Jamieson CH
    J Clin Oncol; 2008 Jun; 26(17):2911-5. PubMed ID: 18539972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
    Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small molecule compound IX inhibits telomere and attenuates oncogenesis of drug-resistant leukemia cells.
    Li Y; Gu J; Ding Y; Gao H; Li Y; Sun Y; He M; Zhang W; Yin J; Bai C; Gao Y
    FASEB J; 2020 Jul; 34(7):8843-8857. PubMed ID: 32433826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for targeting malignant stem cells in leukemia.
    Guzman ML; Jordan CT
    Cancer Control; 2004; 11(2):97-104. PubMed ID: 15024346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.
    Zhang B; Li L; Ho Y; Li M; Marcucci G; Tong W; Bhatia R
    J Clin Invest; 2016 Mar; 126(3):975-91. PubMed ID: 26878174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
    Hu Y; Chen Y; Douglas L; Li S
    Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
    Morotti A; Panuzzo C; Fava C; Saglio G
    Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.